Professor Jian-Gao Fan
Dr. Jian-Gao Fan received his B.Sc. and M.Sc. degrees in 1994 at the Shandong Medical University, and his Ph.D. in 1997 at the Shanghai Second Medical University, respectively, both in China.
He was a Gastroenterologist and then also Associate Professor at Shanghai 1 st People’s Hospital from 1997 to 2007. He was a Visiting Scholar of Australian National University Medical School (Canberra, Australia) from 2007 to 2008. Then and up to now, he is Professor and Director of Center for Fatty Liver & Department of Gastroenterology at Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, and Principle Investigator of Shanghai Key Lab of Pediatric Gastroenterology and Nutrition.
Currently, he is Editor-in-Chief of Chinese Journal of Practical Hepatology, president of Committee on Fatty Liver Diseases, Chinese Physicians' Association, past-president for Shanghai Association for the Study of Liver Diseases, and past-chief of The China National Study Group on Fatty Liver and Alcoholic Liver Disease. He is a member of the editorial board of more than 20 journals, i.e., Clin Mol Hepatol., J Clin Trans Hepatol, J Dig Dis, HBPD INT, World J Gastroenterol, and also lots major journals’ peer-reviewers, i.e., Nat Rev Gastroenterol Hepatol, Gastroenterology, Hepatology, Arch Intern Med, Diabetes Care, J Hepatol.
His main research interests are in the fields of metabolic syndrome and chronic liver diseases. He has published over 700 peer-reviewed academic papers (including over 127 articles in SCI journals as the first and/or correspondent author, i.e, Nat Rev Gastroenterol Hepatol, Hepatology, J Hepatol, Aliment Pharmacol Ther., Cell Mol Gastroenterol Hepatol.,Cancer Lett, EBioMedicine, Liver Int, Exp Mol Med, and 5 book chapters in English) with H-index 51, and 19 books as editor-in-chief, i.e, 1 st & 2 nd Edition, Fatty Liver Disease in China People’s Medical Publishing House. He was co-chairman of the Biennial Shanghai International Forum on Digestive Diseases between 2010-2021, and invited speaker in over 20 countries and regions.
Representative Publications
[1] Ren TY, Fan JG*. What are the clinical settings and outcomes of lean NAFLD?. Nat Rev Gastroenterol Hepatol 2021;18(5):289-290. IF:46.802
[2] Zhao ZH#, Wang ZX#, Zhou D, Han Y, Ma F, Hu Z, Xin FZ, Liu XL, Ren TY, Zhang F, Xue Y, Cui A, Liu Z, Bai J, Liu Y, Cai G, Su W, Dai X, Shen F, Pan Q, Li Y*, Fan JG*.Sodium butyrate supplementation inhibits hepatic steatosis by stimulating liver kinase B1 and insulin-induced gene. Cell Mol Gastroenterol Hepatol. 2021 May 11:S2352-345X(21)00095-3. doi: 10.1016/j.jcmgh.2021.05.006. IF:9.225
[3] Liu XL, Pan Q, Cao HX, Xin FZ, Zhao ZH, Yang RX, Zeng J, Zhou HP, Fan JG*. Lipotoxic Hepatocyte-Derived Exosomal miR-192-5p Activates Macrophages via Rictor/Akt/FoxO1 Signaling in Nonalcoholic Fatty Liver Disease. Hepatology. 2020;72(2):454-469. IF:17.425
[4] Shen F, Zheng RD, Mi YQ, Wang XY, Pan Q, Chen GY, Cao HX, Chen ML, Xu L, Chen JN, Cao Y, Zhang RN, Xu LM, Fan JG*. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis. Aliment Pharmacol Ther. 2019;50(1):93-102. IF: 7.731
[5] Zhao ZH, Xin FZ, Xue YQ, Hu ZM, Han YM, Ma FG, Zhou D, Liu XL, Cui AY, Liu ZS, Liu YX, Gao J, Pan Q, Li Y*, Fan JG*. Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats. Exp Mol Med. 2019; 51(9):103. IF:5.418, 8.718
[6] Zhou D, Chen YW, Zhao ZH, Yang RX, Xin FZ, Liu XL, Pan Q, Zhou H*, Fan JG*. Sodium butyrate reduces high fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression. Exp Mol Med. 2018; 50(12):157. IF:5.584
[7] Fan JG*, Kim SU, Wong Vincent WS*. New Trends on Obesity and NAFLD in Asia. J Hepatol, 2017; 67:862-873. IF: 14.911
5th, 6th, 7th and 8th June 2024
.2024-05-21-16-05-34.svg)
10:00-12:00
Sanofi booth
.2023-01-30-10-21-42.png)
